Evidence map›Paper›PMID 38194196›Full record

ArticleJournal of neuro-oncology2024

Volumetric growth rate of incidentally found meningiomas on immunotherapy.

Assaf Berger, Reed Mullen, Kenneth Bernstein, Elad Mashiach, Ying Meng, Joshua S Silverman, Erik P Sulman, John G Golfinos, Douglas Kondziolka

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Assaf Berger *Department of Neurological Surgery, NYU Langone Health Medical Center, New York University, New York, USA. aberger@ubns.com.
Reed Mullen *Department of Neurological Surgery, NYU Langone Health Medical Center, New York University, New York, USA.
Kenneth BernsteinDepartment of Radiation Oncology, NYU Langone Health Medical Center, New York University, New York, USA.
Elad MashiachDepartment of Neurological Surgery, NYU Langone Health Medical Center, New York University, New York, USA.
Ying MengDepartment of Neurological Surgery, NYU Langone Health Medical Center, New York University, New York, USA.
Joshua S SilvermanDepartment of Radiation Oncology, NYU Langone Health Medical Center, New York University, New York, USA.
Erik P SulmanDepartment of Radiation Oncology, NYU Langone Health Medical Center, New York University, New York, USA.
John G GolfinosDepartment of Neurological Surgery, NYU Langone Health Medical Center, New York University, New York, USA.
Douglas KondziolkaDepartment of Neurological Surgery, NYU Langone Health Medical Center, New York University, New York, USA.
NYU Langone Health · USNeurological Surgery · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe expression of PD-L1 in high-grade meningiomas made it a potential target for immunotherapy research in refractory cases. Several prospective studies in this field are still on going. We sought to retrospectively investigate the effects of check-point inhibitors (CI) on meningiomas that had been naïve to either surgical or radiation approaches by following incidental meningiomas found during treatment with CI for various primary metastatic cancers.

methodsWe used the NYU Perlmutter Cancer Center Data Hub to find patients treated by CI for various cancers, who also had serial computerized-tomography (CT) or magnetic-resonance imaging (MRI) reports of intracranial meningiomas. Meningioma volumetric measurements were compared between the beginning and end of the CI treatment period. Patients treated with chemotherapy during this period were excluded.

resultsTwenty-five patients were included in our study, of which 14 (56%) were on CI for melanoma, 5 (20%) for non-small-cell lung cancer and others. CI therapies included nivolumab (n = 15, 60%), ipilimumab (n = 11, 44%) and pembrolizumab (n = 9, %36), while 9 (36%) were on ipilimumab/nivolumab combination. We did not find any significant difference between tumor volumes before and after treatment with CI (1.31 ± 0.46 vs. 1.34 ± 0.46, p=0.8, respectively). Among patients beyond 1 year of follow-up (n = 13), annual growth was 0.011 ± 0.011 cm

conclusionCheck-point inhibitors may impact the natural history of meningiomas. Additional research is needed to define potential clinical indications and treatment goals.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsMeningeal NeoplasmsMeningiomaHumansImmunotherapyIpilimumabNivolumabProspective StudiesRetrospective StudiesIpilimumabNivolumabCheck-point inhibitorsImmunotherapyMeningiomaVolumetrics

Identifiers

PMID38194196
OpenAlexW4390725094

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.